Published online before print March 22, 2007, doi: 10.1161/01.RES.0000264508.47717.6b
© 2007 American Heart Association, Inc.
Clinical Research |
Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure
Results of the TOPCARE-CHD Registry
From Cardiology and Molecular Cardiology, Department of Medicine III (B.A., U.F.-R., J.H., F.H.S., S.F., V.S., S.D., A.M.Z.), J.W. Goethe University of Frankfurt; and Institute for Transfusion Medicine and Immunohematology (T.T., E.S.), Red Cross Blood Donor Service Baden–Württemberg-Hessen, Frankfurt am Main, Germany.
Correspondence to Andreas M. Zeiher, (Cardiology) Department of Medicine III, J.W. Goethe University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. E-mail zeiher{at}em.uni-frankfurt.de
Although intracoronary administration of bone marrow–derived mononuclear progenitor cells (BMCs) may be associated with improved cardiac function in patients with chronic postinfarction heart failure, the impact on prognosis and clinical outcome of these patients is unknown. To identify potential predictors for a favorable clinical outcome, we assessed natriuretic peptide serum levels as objective markers of heart failure and the occurrence of cardiac death in relation to functional capacity of the infused cells in a consecutive series of 121 patients with chronic ischemic heart disease treated with intracoronary infusion of BMCs. Our analyses show that both N-terminal pro–brain natriuretic peptide (NT-proBNP) and N-terminal pro–atrial natriuretic peptide (NT-proANP) serum levels were significantly reduced in patients with established postinfarction heart failure 3 months after transcoronary progenitor cell administration. NT-proBNP serum levels greater than or equal to median (735 pg/mL) at baseline and a high number of infused progenitor cells with colony-forming capacity were the only independent predictors of a favorable response 3 months after intracoronary administration of BMCs. During extended clinical follow-up (577±442 days), a total of 14 deaths occurred in the overall patient population. Kaplan–Meier curves for both all cause and cardiac mortality showed that patients receiving a higher number of colony-forming cells were significantly less likely to die than those patients receiving low numbers of colony-forming cells (P=0.01). Most importantly, infusion of a high number of cells with colony-forming capacity was associated with a complete abrogation of increased mortality in patients with elevated NT-proBNP serum levels (
735 pg/mL; median) at baseline (P<0.001). Taken together, our results show that patients with objective evidence of postinfarction heart failure demonstrate a significant reduction of both NT-proBNP and NT-proANP serum levels within 3 months following intracoronary infusion of BMCs. Importantly, infusion of progenitor cells with a high functional capacity is associated with a significantly lower mortality during further follow-up.
Key Words: progenitors cells • ischemic cardiomyopathy • NT-proBNP
Related Article:
Circ. Res. 2007 100: 1101-1103.
This article has been cited by other articles:
 |
|
 |
|
  J. K. Willmann, R. Paulmurugan, M. Rodriguez-Porcel, W. Stein, T. J. Brinton, A. J. Connolly, C. H. Nielsen, A. M. Lutz, J. Lyons, F. Ikeno, et al. Imaging Gene Expression in Human Mesenchymal Stem Cells: From Small to Large Animals Radiology, July 1, 2009; 252(1): 117 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Penn Importance of the SDF-1:CXCR4 Axis in Myocardial Repair Circ. Res., May 22, 2009; 104(10): 1133 - 1135. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ebelt, Y. Zhang, A. Kampke, J. Xu, A. Schlitt, M. Buerke, U. Muller-Werdan, K. Werdan, and T. Braun E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo Cardiovasc Res, November 1, 2008; 80(2): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dimmeler and A. Leri Aging and Disease as Modifiers of Efficacy of Cell Therapy Circ. Res., June 6, 2008; 102(11): 1319 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Povsic and P. J. Goldschmidt-Clermont Review: Endothelial progenitor cells: markers of vascular reparative capacity Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 199 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Mieno, R. T. Clements, M. Boodhwani, N. R. Sodha, B. Ramlawi, C. Bianchi, and F. W. Sellke Characteristics and Function of Cryopreserved Bone Marrow-Derived Endothelial Progenitor Cells Ann. Thorac. Surg., April 1, 2008; 85(4): 1361 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases JAMA, February 27, 2008; 299(8): 925 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rota, J. Kajstura, T. Hosoda, C. Bearzi, S. Vitale, G. Esposito, G. Iaffaldano, M. E. Padin-Iruegas, A. Gonzalez, R. Rizzi, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo PNAS, November 6, 2007; 104(45): 17783 - 17788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Hammond Skeletal Muscle-Derived Stem Cell Transplantation: Angiogenesis Is Required for Improved Left Ventricular Function J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1685 - 1687. [Full Text] [PDF]
|
|
|
|
|
|
T. Tang and H. K. Hammond Cell-Based GATA4 Cardiac Gene Transfer Using Cell-Penetrating Peptide Circ. Res., June 8, 2007; 100(11): 1540 - 1542. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Penn Patient and Cellular Characteristics Determine Efficacy of Cell Therapy Circ. Res., April 27, 2007; 100(8): 1101 - 1103. [Full Text] [PDF]
|
|